Non-invasive quantification of brain tumor-induced astrogliosis

Jisook Lee, Alexandra K Borboa, Andrew Baird, Brian P Eliceiri*

Abstract

Background: CNS injury including stroke, infection, and tumor growth lead to astrogliosis, a process that involves upregulation of glial fibrillary acidic protein (GFAP) in astrocytes. However, the kinetics of astrogliosis that is related to these insults (i.e. tumor) is largely unknown.

Results: Using transgenic mice expressing firefly luciferase under the regulation of the GFAP promoter (GFAP-luc), we developed a model system to monitor astrogliosis upon tumor growth in a rapid, non-invasive manner. A biphasic induction of astrogliosis was observed in our xenograft model in which an early phase of activation of GFAP was associated with inflammatory response followed by a secondary, long-term upregulation of GFAP. These animals reveal GFAP activation with kinetics that is in parallel with tumor growth. Furthermore, a strong correlation between astrogliosis and tumor size was observed.

Conclusions: Our results suggest that non-invasive, quantitative bioluminescent imaging using GFAP-luc reporter animal is a useful tool to monitor temporal-spatial kinetics of host-mediated astrogliosis that is associated with glioma and metastatic brain tumor growth.

* Correspondence: beliceiri@ucsd.edu
Department of Surgery, University of California San Diego, San Diego, CA, USA

© 2011 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Results and Discussion
Immunohistochemical analysis of GFAP activity in tumor-bearing brain

To determine the effect of orthotopic tumor xenografts on GFAP activity we subjected immunodeficient Rag2−/− mice (i.e. T and B cells defective) [9] to stereotactic injection with DBTRG glioma cells as described in the Methods. These glioma cells have been previously shown to be highly invasive with infiltrative, satellite tumors distant from the primary tumor [10-12]. Both primary and infiltrative tumors induce specific remodeling of the surrounding microenvironment, which has been analyzed by immunohistochemical analyses of cell-type specific markers, for example, GFAP, to detect remodeling and activation of the astrocytes [10]. In agreement with previous observations from our laboratory and others [10,13-16], GFAP activity was highly upregulated at the tumor margin and adjacent tissue forming a glial scar, whereas a decrease in GFAP immunoreactivity was observed in the tumor core (Figure 1). Although GFAP is generally detected in primary glial brain tumors, its expression is often lost in cell lines established from malignant gliomas such as DBTRG cells [17,18]. Thus, scattered GFAP immunoreactivity inside the tumor was likely from infiltrating astrocytes from the host rather than from the human DBTRG tumor cells themselves. Previous observations using a different astrocyte marker, Aldh1L1 (a marker for protoplasmic astrocytes) [19] demonstrate a similar immunostaining pattern with GFAP (i.e. upregulation at the tumor margin, but decrease in the tumor core). However, aquaporin 4 (AQP4, a marker for astrocytic endfeet) immunoreactivity was upregulated in the tumor core and, moreover, contact with endothelial cells was lost inside tumors [10], indicating that distinct subsets of astrocytes react differently upon glioma growth.

While these immunohistochemical techniques are useful for understanding tumor-induced host remodeling at a cellular level, they rely on the availability and validation of species-specific antibodies to distinguish tumor vs host compartment responses. To develop a rapid, quantitative model to better understand the temporal progression of astrocytic gliosis upon tumor growth, we used GFAP-luc reporter animals for a non-invasive detection of tumor-induced astrogliosis.

Non-invasive imaging analyses of glioma-induced GFAP activation

To determine the effect of orthotopic tumor growth on GFAP promoter-mediated luciferase activity, we back-crossed GFAP-luc mice to an immunodeficient Rag2−/− background. We then injected lentiviral-transduced, DBTRG cells expressing red fluorescent protein (DBTRG-RFP) into the brains of 10 week-old GFAP-luc; Rag2−/− mice by stereotactic injection. Intracranial injections of an equal volume of PBS were used to control for injury induced by the injection itself. As reported earlier [6,20], intracranial injections of PBS alone induced a transient injury response, which was

Figure 1 Using standard immunohistochemical technique to assess GFAP activity in tumor-bearing brain. (A) DBTRG glioma cells were introduced into mice by stereotactic injection. Following three weeks incubation, brains were harvested and sections were made to measure GFAP activity in tumor bearing vs. contralateral brain by immunohistochemistry. Sections were counterstained with DAPI and tumor area was defined by dense nuclei staining of the tumor cells (dotted line). An example of exposure-matched images of tumor-bearing brain (right) and its contralateral hemisphere (left) is shown. Note the upregulated GFAP activity at the tumor margin (right). Scale bar = 1 mm. (B) Fluorescently labeled DBTRG-Zsgreen glioma cells (green) were introduced into mice by stereotactic injection. Following three weeks incubation, brains were harvested and sections were made to measure GFAP activity (red) by immunohistochemistry. A representative image of upregulated GFAP immunoreactivity at the tumor margin compared to the tumor core is shown. Scale bar = 100 μm. (C) GFAP immunoreactivity in tumor margin (defined by fluorescent activity of the tumor cells), tumor core vs. normal area (contralateral) was quantified by measuring the fluorescent intensity of images in panel (B). Results are shown as an average of three mice. At least three independent areas were quantified from each mouse. P < 0.05, Wilcoxon rank sum test, two-sided. Error bar represents standard deviation.
Non-invasive imaging analyses of metastatic brain tumor-induced GFAP activation

Metastatic brain tumors also induce reactive astrogliosis in the brain [21,22], therefore, we tested whether cancer cells of non-CNS origin activate GFAP in our model. Following stereotactic injection of MDA-MB231 human breast cancer cells, we observed similar results (i.e. biphasic activation of luciferase upon tumor implantation)(Figure 3). These data indicate that the GFAP-luc; Rag2−/− mice are useful tools to monitor reactive tumor-induced astrogliosis of the host compartment non-invasively.

Real time monitoring of spatial distribution of host-mediated astrogliosis

To understand the spatial distribution of GFAP-activation relative to the tumor in real-time, we generated a three-dimensional reconstruction of astrogliosis in tumor-bearing mice using Living Image 4.0 (Caliper Life Science). GFAP-luc; Rag2−/− mice were injected with RFP-labeled DBTRG glioma cells and incubated for four weeks. We observed a localized tumor mass in the cortex, while GFAP activity was upregulated more broadly in the areas surrounding the tumor (Figure 4). In agreement with the immunohistochemical data (Figure 1), there was not a complete overlap between the tumor area and GFAP activity suggesting that the GFAP response in the host is not a complete overlap between the tumor area and GFAP activity.

GFAP activation correlates with tumor size

To determine whether astrogliosis was restricted to the tumor region or a global astrocyte response was generated
as a consequence of tumor growth, we monitored luciferase activity in brain sections. Following a four-week incubation of glioma in vivo, the brain was harvested and 1 mm brain sections were prepared. Consistent with the immunohistochemical data (Figure 1), reactive astrogliosis was observed only in tumor-bearing sections and sections adjacent to tumors (Figure 5A). Furthermore, we observed a statistically significant correlation between tumor size (i.e. fluorescent intensity of RFP-labeled glioma cells) and astrogliosis (i.e. GFAP-mediated luciferase activity) (Figure 5B, p < 0.01).

GFAP immunostaining (Figure 1) and our bioluminescent reporter model (Figure 4 and 5) both indicated that tumor induced-GFAP activity was mainly observed in the microenvironment of the tumor. On the other hand, GFAP activity in the contralateral hemisphere (adjacent to tumor-bearing hemisphere) was very low and close to the baseline activity of GFAP observed in control brain without injury. Although we have found a significant correlation between the tumor size and astrogliosis in the tumor microenvironment, we did not observe a significant change of global GFAP activity (i.e. non-tumor bearing brain slabs of tumor-bearing animals) based on tumor size.

In mouse EAE and prion infection models there is a direct correlation between the amount of GFAP-mediated luciferase activity and the intensity of the insult [6,8]. Yet, in the mouse model of ischemic injury in the CNS, a correlation between the GFAP activity and infarct size was observed only in the male mice [7]. Although not a focus of these studies, we did not observe any differences in the GFAP activity upon tumor growth between male and female animals. However, other tools to monitor astrogliosis maybe useful to assess gender differences in future studies.

We established that transgenic GFAP-luc reporter mice are useful to study the interaction of the tumor growth and astrogliosis. The non-invasive nature of this

Figure 4 Spatial distribution of host-mediated astrogliosis. (A) 3D images using diffuse tomographic reconstruction algorithms for fluorescence (RFP-labeled tumor) or bioluminescent sources (GFAP activity, luciferase) were created with tumor-bearing GFAP-luc mice after a four-week incubation. Representative coronal, sagittal, and transaxial images from the center of the tumor is shown. Note the upregulation of GFAP activity adjacent to the tumor (merged image). (N = 3). (B) 3D reconstruction of fluorescent or bioluminescent sources in the whole animal is shown. While fluorescent signal from tumor was localized, GFAP activity was upregulated at the tumor periphery. Merged images from dorsal, left side, ventral and right side is shown. A representative image of three independent experiments is shown.

Figure 5 GFAP activation correlates with tumor location and tumor size. (A) GFAP-luc mice were injected with RFP-labeled human glioma cells, incubated for 4 weeks and six 1 mm coronal brain sections (numbered 1-6, anterior to posterior) were made for each animal. Tumor (red, left panel) and tumor-induced GFAP activation (luciferase, right panel) were localized in the same sections. A representative image of brain sections is shown. (B) Tumor burden (measured by its fluorescent intensity) and GFAP activation (measured by luciferase activity) from four tumor-bearing animals (at least five sections from each animal) were quantified. GFAP activity correlates with tumor size. Kendall’s rank correlation test, two-sided, coefficient index τ = 0.54, P < 0.01.
model can be used for the dynamic assessment of astrogliosis during the course of tumor treatment after the delivery of chemotherapeutic drugs or early detection of a recurring tumor. Transgenic reporter models such as GFAP-luc provide insights into the molecular physiology of the tumor microenvironment which maybe useful for drug discovery or screening [23] and evaluating other transgenic models for host compartment specific response to glioma growth and invasion.

Conclusions
Together, these results indicate that GFAP activity can be used as a surrogate marker for tumor-induced astrogliosis. Unlike the traditional methods to monitor astrogliosis, these reporter mice can be utilized for rapid, quantitative, and dynamic assessments of the tumor-host interaction.

Methods
Animals
GFAP-luc transgenic mice (FVB/N-Tg(Gfap-luc)-Xen) expressing the firefly luciferase gene under the control of 12 kb murine GFAP promoter were obtained from Caliper Life Sciences (Hopkinton, MA). These animals were backcrossed into a Rag2−/− immunodeficient background (i.e. T and B cell deficient) for at least five generations to avoid rejections of the xenograft [9]. Mice were genotyped by quantitative PCR using primers specific for the luciferase transgene (Transnetyx Inc). Mice that did not show baseline GFAP activity (measured by luciferase activity before intracranial injection) were excluded from the study. All animal husbandry and handling procedures were approved by the University of California San Diego Institutional Animal Care and Use Committee.

Tumor cells
Early passages of patient-derived human glioma cells, DBTRG (a kind gift from Dr. C. Kruse) [18] were used in xenograft studies. These DBTRG cells were transduced with lentivirus expressing red fluorescent protein (DBTRG-RFP) or Zsgreen (DBTRG-Zsgreen) as described earlier [10,12] to enable their identification from normal CNS parenchyma. MDA-MB-231 breast cancer cells were obtained from ATCC. All cells were maintained in Dulbecco’s modified Eagle’s minimum essential medium supplemented with 10% fetal bovine serum, penicillin, streptomycin, nonessential amino acids, and glutamine in a humidified atmosphere containing 5% CO2 at 37°C.

Intracranial stereotactic injections
10 week-old mice were immobilized in a rodent stereotactic frame, an incision made in the skin, and a burr hole made in the skull. One million tumor cells resuspended in 5 μl of PBS were injected at a rate of 1-2 μl/minute using a Hamilton microsyringe (Hamilton, Reno, NV) mounted on a stereotactic frame (Kopf Instruments, Tujunga, CA) using coordinates of 1 mm lateral and 2 mm posterior to the bregma and 2 mm below the dura. The incision was closed with sterile sutures. Equal volume of PBS (5 μl) was used as controls.

Quantification of bioluminescent imaging in vivo
Astrogliosis was monitored before (i.e. pre-operation) and following of incubation of 3, 7, 14, 21 and 28 days post-injection for tumor growth. Fur was removed from mice with electric clippers and Nair (Church & Dwight Co., Inc., Princeton, NJ) before imaging at each time point. Bioluminescent signals were assessed 10 minutes after intraperitoneal D-luciferin injection (150 μl of 15 mg/ml stock) using a cooled charge-coupled device (CCD) camera (Spectrum; Caliper Life Sciences, Hopkinton, MA) capable of in vivo imaging (using settings of exposure time 2-10 sec, large binning, F/Stop = 1). GFAP activity was monitored by quantification of light emission from a region of interest (ROI) at each time point (Unit = radiance). Bioluminescent signal from the ear represents basal level of GFAP activity and were excluded from the ROI. Images were analyzed using Living Image software version 4.0 (Caliper Life Sciences, Hopkinton, MA).

3D reconstruction of bioluminescent and fluorescent signals
Gray-scale photographs and structured-light images were collected to generate a 3D reconstruction of the surface of the mice. 3D images were created using diffuse tomographic reconstruction algorithms for fluorescence (Fluorescent Imaging Tomography, FLIT) or bioluminescent sources (Diffused Luminescent Imaging Tomography, DLIT) with Living Image software version 4.0. Bioluminescent signals were assessed 10 minutes after D-luciferin injection (at the steady-state of luciferin kinetic profile).

Immunohistochemistry
Three weeks after implantation, the animals were perfused with heparin/saline by intracardiac injection, the brains harvested and cryoembedded in O.C.T. medium (Miles Inc, Kankakee, IL). Standard immunohistochemistry was performed on cryosections (10 μm) of tumor samples using the mouse monoclonal anti-GFAP (C9205, Sigma, St.Louis, MO, 1:200) and Alexa-fluor-conjugated secondary antibodies (Invitrogen, Carlsbad, CA, 1:200). All sections were counterstained with 0.5 μg/ml DAPI (Sigma, St.Louis, MO) and tumor area defined either by the typical dense nuclei staining of the tumor (Figure 1A) or fluorescent activity of the tumor cells (Figure 1B). Immunostaining of tissue sections
were imaged with an Olympus Fluoview 1000 (ASW 1.7 b) laser scanning confocal microscope equipped with 2x/0.08 N.A., 10x/0.4N.A. and 20x/0.7N.A. dry-objective lenses on a BX61 microscope (Olympus, Center Valley, PA). GFAP immunoreactivity was quantified by defining a region of interest (ROI) and by measuring the total fluorescent units in the ROI in exposure-matched images using Olympus Fluoview (ASW 1.7 b) software.

Ex vivo analyses

Four weeks after tumor implantation, tumor-bearing brain was harvested and 1 mm thick brain sections were made. Tumor burden (measured by fluorescence of RFP-labeled tumor cells) and astrogliosis (measured by bioluminescence of GFAP-luc reporter) was quantitated. Tumor burden (measured by fluorescence of GFAP-luc reporter) was quantitated with a deep-cooled CCD imaging system equipped with appropriate fluorescence filter cubes with background subtraction. Images were analyzed using Living Image software version 3.1.

Statistical analyses

All statistical analyses were performed using Mstat software (version 3.1) with a deep-cooled CCD imaging system equipped with appropriate fluorescence filter cubes with background subtraction.

Additional material

Additional file 1: Spatial distribution of host-mediated astrogliosis

A movie of 3D reconstruction of fluorescent RFP-labeled tumor and bioluminescent sources (GFAP activity, luciferase) in tumor-bearing GFAP-luc mice after a four-week incubation is shown.

List of abbreviations

BBB: blood-brain barrier; CCD: charge-coupled device; CNS: central nervous system; EAE: experimental autoimmune encephalomyelitis; GFAP: glial fibrillary acidic protein.

Acknowledgements and Funding

These studies were supported by grants from the NHLBI, NINDS (BE) and Mr. and Mrs. William Jackson American Brain Tumor Association Basic Research Fellowship (JL).

Authors’ contributions

JL, AB and BPE designed research; JL and AKB performed research; JL and BPE analyzed data; JL, AB, and BPE wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 19 October 2010 Accepted: 19 January 2011 Published: 19 January 2011

References

1. Jain RK. Normalization of tumor vasculature an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
2. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50(4):427-434.
3. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009, 32(12):638-647.
4. Edelstein M, Mucke L. Molecular profile of reactive astrocytes–implications for their role in neurologic disease. Neuroscience 1993, 54(1):15-36.
5. Zhu L, Ramboz S, Hewitt D, Boring L, Grass DS, Purdie EH. Non-invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett 2004, 367(2):210-212.
6. Tamguneey G, Francis KP, Giles K, Lemus A, Darremond SJ, Prusiner SB. Measuring prions by bioluminescence imaging. Proc Natl Acad Sci USA 2009, 106(35):15002-15006.
7. Condeau P Jr, Lalancette-Hebert M, Weng YC, Koz J. Live imaging of neuroinflammation reveals sex and estrogen effects on astrocyte response to ischemic injury. Stroke 2008, 39(3):935-942.
8. Luo J, Ho P, Steinman L, Wiss-Coray T. Bioluminescence in vivo imaging of autimmune encephalomyelitis predicts predicts disease. J Neuroimmunol 2006, 18(6).
9. Shinkai Y, Rathbun G, Lamm K, Otz EM, Stewart V, Mendelsohn M, Charon J, Datta M, Young F, Stall AM, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992, 68(5):855-867.
10. Lee J, Lund-Smith C, Borboa A, Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, Vega-Lu M, Ellison BP. Glial-induced remodeling of the neurovascular unit. Brain Res 2009, 1288:125-134.
11. Lund CV, Nguyen MT, Owens CC, Pakhiaus AJ, Shaterian A, Krizek CA, Elices BP. Reduced glioma infiltration in Src-deficient mice. J Neurooncol 2006, 78(1):19-29.
12. Lee J, Borboa AK, Chun HB, Baird A, Elices BP. Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma. Cancer Res 70(20):10313-10140.
13. Le DM, Beison A, Fogk DJ, Choi KS, Waisman DM, Goodyer CG, Newcastle B. Morphogenesis of astrocytes by glioma cells to brain facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 2005, 25(30):4034-4043.
14. deCanvallo AC, Zhang X, Roberts C, Jiang F, Kalkanis SN, Hong X, Lu M, Chopp M. Subclinical photodynamic therapy treatment modifies the brain microenvironment and promotes glioma growth. Glia 2007, 55(10):1053-1060.
15. Sällä B, Angelov L, Ronca L, Wu X, Shannon P, Guha A. Expression of vascular endothelial growth factor by reactive astrocytes and associated neangiogenesis. Brain Res 2000, 883(1):87-97.
16. Chekhonin VP, Baklaushev VP, Yusubalieva GM, Pavlov KA, Ukhova OV, Gurina OI. Modeling and immunohistochemical analysis of C6 glioma in vivo. Bull Exp Biol Med 2007, 143(4):501-509.
17. Bignard HD, Bullard DE, Prusiner SB, Wiet JJ. Characterization of a continuous human glioma cell line D8TRG-05MG: growth kinetics, cytotoxicity, receptor expression, and tumor suppressor genes. In Vivo Cell Dev Biol 1992, 28A(4):609-614.
18. Cahoy JD, Emery B, Kauhal A, Foe LC, Zamanian JL, Christopherson KS, Xing Y, Lubescher JL, Krieg PA, Krupenko SA, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008, 28(1):264-278.
19. Maysinger D, Behrendt M, Lalancette-Hebert M, Koz J. Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett 2007, 7(8):2513-2520.
20. Zhang M, Olsson Y. Hematogenous metastases of the human brain–characteristics of peritumoral brain changes: a review. J Neurooncol 1997, 35(1):81-89.
21. Fitzgerald DP, Palmieri D, Hua E, Hardge E, Hargrave E, Haring JM, Qian Y, Vega-Valle E, Weil R, Stark AM, Vortmeyer AO, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008, 25(7):799-810.
23. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25(16):2295-2305.

doi:10.1186/1471-2202-12-9

Cite this article as: Lee et al.: Non-invasive quantification of brain tumor-induced astrogliosis. BMC Neuroscience 2011 12:9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit